Tasquinimod

Summary

Tasquinimod (CHEMBL2107784) is a phase-3 clinical-stage small molecule targeting HDAC4; indicated across 5 conditions including metastatic prostate carcinoma and prostate adenocarcinoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Targets: 1 (HDAC4)
• Indications: 5 conditions
• Clinical trials: 11
• Chemistry: 406.4 Da · C20H17F3N2O4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2107784
Name	Tasquinimod
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	54682876
Molecular formula	C20H17F3N2O4
Molecular weight	406.4
InChIKey	ONDYALNGTUAJDX-UHFFFAOYSA-N

SMILES: CN1C2=C(C(=CC=C2)OC)C(=C(C1=O)C(=O)N(C)C3=CC=C(C=C3)C(F)(F)F)O

IUPAC name: 4-hydroxy-5-methoxy-N,1-dimethyl-2-oxo-N-[4-(trifluoromethyl)phenyl]quinoline-3-carboxamide

Also known as: Tasquinimod, TASQUINIMOD

Patent coverage: 461 distinct patent families (1,248 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 1,224 (98%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
HDAC4	histone deacetylase 4	Inhibition	8	3.1%	P56524

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Histone deacetylase 4.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 2 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
HDAC4	8	Kd	10	nM	CHEMBL_ACT_22974917
HDAC4	8	Kd	10	nM	CHEMBL_ACT_24867613

Target pathways

Aggregated over 1 target gene(s): HDAC4.

Top Reactome pathways

9 total, by targets touching each:

Pathway	Targets	Genes
NOTCH1 Intracellular Domain Regulates Transcription	1	HDAC4
Constitutive Signaling by NOTCH1 PEST Domain Mutants	1	HDAC4
Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants	1	HDAC4
Notch-HLH transcription pathway	1	HDAC4
SUMOylation of intracellular receptors	1	HDAC4
SUMOylation of chromatin organization proteins	1	HDAC4
RUNX2 regulates chondrocyte maturation	1	HDAC4
RUNX3 regulates p14-ARF	1	HDAC4
Differentiation of naive CD4+ T cells to T helper 2 cells (Th2 cells)	1	HDAC4

Dominant GO biological processes

GO term	Targets
negative regulation of transcription by RNA polymerase II	1
chromatin remodeling	1
inflammatory response	1
nervous system development	1
positive regulation of cell population proliferation	1
negative regulation of myotube differentiation	1
obsolete negative regulation of transcription by competitive promoter binding	1
response to denervation involved in regulation of muscle adaptation	1
cardiac muscle hypertrophy in response to stress	1
protein sumoylation	1
B cell differentiation	1
positive regulation of protein sumoylation	1
epigenetic regulation of gene expression	1
B cell activation	1
negative regulation of gene expression, epigenetic	1

Indications & clinical

Indications

5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
metastatic prostate carcinoma	3	MONDO:0004956	EFO:0000196
prostate adenocarcinoma	3	MONDO:0005082	EFO:0000673
prostate carcinoma	3	MONDO:0005159	EFO:0001663
plasma cell myeloma	1	MONDO:0009693	EFO:0001378

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 11.

Phase distribution

Phase	Trials
PHASE2	4
PHASE1	3
PHASE3	2
PHASE1/PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01234311	PHASE3	COMPLETED	A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
NCT02057666	PHASE3	TERMINATED	Study Of Tasquinimod In Asian Chemo-Naïve Patients With Metastatic Castrate-Resistant Prostate Cancer
NCT06327100	PHASE1/PHASE2	RECRUITING	Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)
NCT06605586	PHASE1/PHASE2	RECRUITING	Tasquinimod in Patients with Myelofibrosis Refractory to or Intolerant for JAK2 Inhibition
NCT00560482	PHASE2	COMPLETED	Efficacy Study of ABR-215050 to Treat Prostate Cancer
NCT01732549	PHASE2	TERMINATED	A Proof of Concept Study of Maintenance Therapy With Tasquinimod in Patients With Metastatic Castrate-resistant Prostate Cancer Who Are Not Progressing After a First Line Docetaxel Based Chemotherapy
NCT01743469	PHASE2	COMPLETED	A Study With Tasquinimod Treating Patients With Hepatocellular, Ovarian, Renal Cell and Gastric Cancers
NCT02159950	PHASE2	COMPLETED	Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
NCT01513733	PHASE1	COMPLETED	The CATCH Prostate Cancer Trial: Cabazitaxel And Tasquinimod in Men With Prostate Cancer
NCT02396368	PHASE1	WITHDRAWN	A Study of Radium-223 in Combination With Tasquinimod in Bone-only Metastatic Castration-Resistant Prostate Cancer
NCT04405167	PHASE1	TERMINATED	Tasquinimod for the Treatment of Relapsed or Refractory Myeloma

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

25 molecules share ≥1 primary target. Top 25 by shared-target count:

Molecule	Source	Status	Shared targets
BELINOSTAT	ChEMBL	Phase 4 (approved)	HDAC4
BENDAMUSTINE	ChEMBL	Phase 4 (approved)	HDAC4
CELECOXIB	ChEMBL	Phase 4 (approved)	HDAC4
GIVINOSTAT	ChEMBL	Phase 4 (approved)	HDAC4
PANOBINOSTAT	ChEMBL	Phase 4 (approved)	HDAC4
PHENYLBUTANOIC ACID	ChEMBL	Phase 4 (approved)	HDAC4
ROMIDEPSIN	ChEMBL	Phase 4 (approved)	HDAC4
SODIUM PHENYLBUTYRATE	ChEMBL	Phase 4 (approved)	HDAC4
VORINOSTAT	ChEMBL	Phase 4 (approved)	HDAC4
ABEXINOSTAT	ChEMBL	Phase 3	HDAC4
CAFFEIC ACID	ChEMBL	Phase 3	HDAC4
CURCUMIN	ChEMBL	Phase 3	HDAC4
ENTINOSTAT	ChEMBL	Phase 3	HDAC4
PRACINOSTAT	ChEMBL	Phase 3	HDAC4
TACEDINALINE	ChEMBL	Phase 3	HDAC4
TUCIDINOSTAT	ChEMBL	Phase 3	HDAC4
AR-42	ChEMBL	Phase 2	HDAC4
CHLOROGENIC ACID	ChEMBL	Phase 2	HDAC4
DACINOSTAT	ChEMBL	Phase 2	HDAC4
FIMEPINOSTAT	ChEMBL	Phase 2	HDAC4
NANATINOSTAT	ChEMBL	Phase 2	HDAC4
QUISINOSTAT	ChEMBL	Phase 2	HDAC4
RICOLINOSTAT	ChEMBL	Phase 2	HDAC4
TINOSTAMUSTINE	ChEMBL	Phase 2	HDAC4
Pazopanib	PubChem	Approved	HDAC4